Meeting Overview - The company will hold its second extraordinary general meeting of shareholders in 2025 on September 12, 2025, at 14:30 [1] - The meeting will be conducted through a combination of on-site and online voting [1] - The online voting will take place on the same day from 9:15 to 15:00 [1] Meeting Agenda - The meeting will start with the announcement of the attendance and qualification of shareholders [2] - The board secretary will read the meeting guidelines [2] - Election of monitors and counters for the meeting will be conducted [2] - Shareholders will have the right to speak, inquire, and vote during the meeting [2][3] Voting Procedures - Voting will be conducted through both on-site and online methods, with specific instructions for marking votes [3][4] - Invalid votes will be considered as abstentions [4] - The counting of votes will be overseen by appointed monitors and a witnessing lawyer [4][6] Proposals for Cash Management - The company proposes to use up to 820 million yuan of idle funds for cash management to enhance fund efficiency and reduce financial costs [4][5] - The investment will focus on high-security and high-liquidity financial products [5][6] - The cash management will be valid for 12 months from the date of approval at the meeting [5][6] Use of Idle Raised Funds - The company plans to use up to 380 million yuan of idle raised funds for cash management, ensuring it does not affect ongoing projects [7][8] - The funds will be sourced from the proceeds of convertible bonds issued to unspecified investors [8][9] - The cash management will also be valid for 12 months from the date of approval [11] Profit Distribution Proposal - The company proposes a cash dividend of 2.40 yuan per share, totaling approximately 95.67% of the net profit for the first half of 2025 [13][14] - The distribution will be based on the total share capital as of August 25, 2025, excluding shares held in the company's repurchase account [14] Governance Changes - The company intends to abolish the supervisory board and amend its articles of association, transferring the supervisory functions to the audit committee of the board [15][16] - The changes aim to enhance corporate governance and align with legal regulations [15][16]

Core Viewpoint - The announcement details the overdue payment situation regarding the "Guomin Trust · Huijin No. 87 Collective Fund Trust Plan," highlighting the company's receipt of a principal amount of 169.99 million yuan and the ongoing efforts to manage the associated loan rights and collateral assets [1][4]. Summary by Sections Situation Overview - The company approved the use of up to 600 million yuan of idle funds for cash management, specifically for purchasing financial products from banks and trust companies, with a maximum investment of 170 million yuan in the "Guomin Trust · Huijin No. 87 Collective Fund Trust Plan" [1]. - The trust plan was established with a total scale of 200 million yuan, with the company contributing 170 million yuan, and as of the maturity date, only 10,000 yuan had been repaid, leaving an outstanding balance of 199.99 million yuan [1]. Progress of Trust Product Purchase - The company, as the trustee, has been actively pursuing the transfer of loan rights related to the trust plan to its subsidiary, Zhizhu Space (Tianjin) Technology Co., Ltd., which has signed a debt transfer agreement with Guomin Trust [2][3]. Subsequent Disposal Work Progress and Plans - Zhizhu Space is tasked with managing the loan rights and collateral assets, including applying to change the executor in a court case and potentially auctioning off collateral properties [4]. - The company emphasizes the importance of effective governance and risk control in overseeing Zhizhu Space's operations and financial management [4]. Impact on the Company - The company recognized a fair value change loss of 17 million yuan in 2022 and 68 million yuan in 2023 due to the trust product, which resulted in a net profit increase of 72.25 million yuan at the parent company level, although the consolidated net profit remains unchanged [5].

证券代码：600713 证券简称：南京医药 公告编号：ls2025-113 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于以集中竞价交易方式回购公司 股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相 关规定，公司在回购期间，应当在每个月的前3个交易日内公告截至上月末的回购进展情况，现将公司 回购股份的进展情况公告如下： 截至2025年8月31日，公司通过集中竞价交易方式已累计回购公司股份1,629.9951万股，占公司2025年8 月末总股本130,892.8704万股的比例为1.25%。累计回购公司股份数与上次披露数相比没有变化，回购 成交的最高价为5.22元/股，最低价为4.69元/股，已支付的资金总额为8,025.76万元（不含交易费用）。 注：因公司发行的可转换公司债券"南药转债"（债券代码"110098"）自2025年7月1日起开始转股，公司 2025年8月末总股本由2025年7月末的13 ...

Group 1 - The company plans to use idle raised funds for cash management, approving an amount not exceeding RMB 532 million to purchase low-risk, highly liquid wealth management products [1][3][7] - The purpose of this cash management is to enhance the efficiency of fund utilization, ensuring it does not affect the construction of investment projects or the company's normal operations [3][14] - The company has established a dedicated settlement account for cash management at a bank, ensuring that the funds are used solely for this purpose [8] Group 2 - The company has already redeemed previous investments made with idle funds, returning both principal and earnings to the dedicated account [9] - The company’s stock experienced a significant price fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days [17][18] - The company confirmed that there are no undisclosed significant matters affecting stock price fluctuations, and its operational activities remain normal [19][20]

Core Viewpoint - The company has approved a cash management plan to utilize temporarily idle raised funds and self-owned funds, aiming to invest in high-security and high-liquidity products [1]. Group 1: Cash Management Approval - The company's board of directors approved a proposal to manage temporarily idle raised funds not exceeding 500 million yuan and self-owned funds not exceeding 100 million yuan [1]. - The supervisory board and the sponsor institution have expressed their agreement with the cash management plan [1]. Group 2: Cash Management Progress - There are no overdue products purchased with temporarily idle raised funds, and as of the announcement date, the balance of products purchased with raised funds is 270 million yuan [1].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603332 证券简称：苏州龙杰 公告编号：2025-042 苏州龙杰特种纤维股份有限公司 关于使用部分闲置自有资金进行现金管理的进展公告 重要内容提示 ： ● 委托理财受托方：江苏张家港农村商业银行股份有限公司；江苏张家港农村商业银行股份有限公司； 招商银行股份有限公司；招商银行股份有限公司 ● 本次委托理财金额： 6,000万元；5,000万元；1,000万元；1,000万元 ● 委托理财产品名称：公司结构性存款2025110期（编号：JGCK2025110）；公司结构性存款2025164期 （编号：JGCK2025164）；招商银行智汇系列看涨两层区间33天结构性存款（产品代码： FSU01166）；招商银行智汇系列看跌两层区间31天结构性存款（产品代码：FSU01239） ● 委托理财期限： 182天；180天；33天；31天 ● 履行的审议程序：苏州龙杰特种纤维股份有限公司（以下简称"公司"、"苏州龙杰" ...

Core Viewpoint - Chongqing Zaiseng Technology Co., Ltd. has announced the use of part of its temporarily idle self-owned funds for cash management by purchasing low-risk financial products, with a maximum investment of RMB 400 million and a management period not exceeding 12 months [2][4]. Group 1: Basic Situation - The company held a board meeting on October 8, 2024, where it approved the proposal to use up to RMB 400 million of temporarily idle self-owned funds for cash management, ensuring that it does not affect the normal development of its main business [2]. - The company purchased RMB 110 million worth of financial products from China Merchants Bank on July 31, 2025, which has now matured and been redeemed [3][4]. Group 2: Risk Control Measures - The company will analyze and monitor the financial products regularly, reporting any adverse factors to the board and taking necessary protective measures [4]. - A cash management product management system has been established to regulate daily management, risk control, and information disclosure [4]. - The audit department is responsible for auditing the use and custody of financial products, with quarterly checks on structured deposit products [4].

证券代码：600713 证券简称：南京医药 编号：ls2025-114 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 现金管理受托方：招商银行股份有限公司（以下简称"招商银行"） ? 本次现金管理金额：9,000万元（人民币，下同） ? 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司福建同春药业股份有限公司（以下简称"福建同春"）本次使用部分暂时闲置 募集资金 9,000 万元购买招商银行点金系列看涨两层区间 91 天结构性存款。 ? 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688515 证券简称：裕太微 公告编号：2025-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 裕太微电子股份有限公司（以下简称"公司"）根据《上市公司募集资金监管规则》《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》等相关规定，结合公司实际情况，就2025年半年度募 集资金存放与实际使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、到位时间 经中国证券监督管理委员会以"证监许可[2022]3202号"文《关于同意裕太微电子股份有限公司首次公开 发行股票注册的批复》核准，同意公司向境内投资者公开发行人民币普通股（A股）股票20,000,000 股，每股面值1.00元，每股发行价格92.00元。截至2023年2月3日，公司募集资金总额为人民币 1,840,000,000.00元，扣除承销费和保荐费（不含增值税）147,200,000.00元后，剩余募集资金 1,692,800,000.00元，已由主承销商于2023年 ...

Core Points - The company Shanghai Hejing Silicon Materials Co., Ltd. has reported on the status of its fundraising activities for the first half of 2025, confirming compliance with relevant regulations and the proper management of raised funds [1][12]. Fundraising Overview - The company issued 66,206,036 shares at a price of 22.66 RMB per share, raising a total of approximately 1.5 billion RMB, with a net amount of about 1.39 billion RMB after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized approximately 868.68 million RMB of the raised funds, leaving a balance of about 537.75 million RMB [2]. Fund Management - The company has established a fundraising management system to ensure the safety and proper use of the raised funds, in accordance with the Shanghai Stock Exchange regulations [2]. - A tripartite supervision agreement has been signed with banks to oversee the management of the fundraising account, ensuring compliance with legal requirements [3]. Cash Management - The company has approved the use of up to 735 million RMB of temporarily idle funds for cash management, focusing on low-risk, high-liquidity financial products [5]. - As of June 30, 2025, the balance of idle funds under cash management was approximately 482.55 million RMB [6]. Fund Usage and Adjustments - There were no instances of using idle funds to temporarily supplement working capital during the reporting period [6]. - The company has not made any changes to the fundraising projects or reported any surplus funds as of June 30, 2025 [11][7]. Project Delays - The timeline for the "High-Quality Epitaxial Wafer R&D and Industrialization Project" has been extended to December 2026 due to market demand changes [10].